Citations 437

CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies

Neurology | August 13, 2021 | Volume: 97 | Issue: 13 | Pages: No page available

10.1212/wnl.0000000000012599 | PMID 34389648

Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders

Neurology | July 14, 2021 | Volume: 97 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000012467 | PMID 34261784

Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder

Multiple Sclerosis Journal | May 12, 2021 | Volume: 28 | Issue: 1 | Pages: 149-153

10.1177/13524585211011450 | PMID 33975499

Background: Optic neuritis (ON) is often the presenting symptom in inflammatory central nervous system demyelinating disorders. Objective: To compare the frequency and pattern of optic chiasm involvement in patients with aquaporin-4-immunoglobulin G (AQP4-IgG)-associated ON to patients with myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG)-associated ON. Methods: Retrospective review of all patients evaluated at Mayo Clinic, Stanford University and Ramathibodi Hospital who were found to have: (1) ON, (2) either MOG-IgG or AQP4-IgG by cell-based assay, and (3) magnetic resonance imaging (MRI) at the time of ON. MRI was reviewed for contrast enhancement of the optic chiasm and the pattern of involvement. Results: One hundred and fifty-four patients (74 AQP4-IgG and 80 MOG-IgG) were included. Among patients with AQP4-IgG-ON, 20% had chiasmal involvement, compared with 16% of patients with MOG-IgG-ON ( p = 0.66). In patients with chiasmal involvement, longitudinally extensive optic nerve enhancement (from orbit extending to chiasm) was identified in 54% of MOG-IgG-ON patients, compared with 7% of AQP4-IgG-ON patients ( p = 0.01). Conclusion: Chiasmal involvement of MOG-IgG-ON and AQP4-IgG-ON occur at more similar frequencies than previously reported. Furthermore, MOG-IgG-ON chiasmal involvement is more likely to be part of a longitudinally extensive optic nerve lesion.
Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels

Neurology | April 26, 2021 | Volume: 96 | Issue: 24 | Pages: No page available

10.1212/wnl.0000000000012050 | PMID 33903199

Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing

JAMA Neurology | April 26, 2021 | Volume: 78 | Issue: 6 | Pages: 741

10.1001/jamaneurol.2021.0912 | PMID 33900394

Clinical Utility of Antiretinal Antibody Testing

JAMA Ophthalmology | April 22, 2021 | Volume: 139 | Issue: 6 | Pages: 658

10.1001/jamaophthalmol.2021.0651 | PMID 33885761

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

Neurology Neuroimmunology & Neuroinflammation | March 26, 2021 | Volume: 8 | Issue: 3 | Pages: No page available

10.1212/nxi.0000000000000978 | PMID 33771837

MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study

JAMA Ophthalmology | March 25, 2021 | Volume: 139 | Issue: 5 | Pages: 583

10.1001/jamaophthalmol.2021.0349 | PMID 33764379

Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity

Epilepsia | March 25, 2021 | Volume: 62 | Issue: 5 | Pages: No page available

10.1111/epi.16888 | PMID 33764529

AbstractThe objective of this study was to describe serological association of musicogenic epilepsy and to evaluate clinical features and outcomes of seropositive cases. Through retrospective chart review, musicogenic epilepsy patients were identified. Among 16 musicogenic epilepsy patients, nine underwent autoantibody evaluations and all had high‐titer glutamic acid decarboxylase 65–immunoglobulin G (GAD65‐IgG; >20 nmol·L–1, serum, normal ≤ .02 nmol·L–1, eight women). Median GAD65‐IgG serum titer was 294 nmol·L–1 (20.3–3005 nmol·L–1), and median cerebrospinal fluid titer (n = 4) was 14.7 nmol·L–1. All patients had temporal lobe epilepsy, and bitemporal epileptiform abnormalities were common. Right temporal lobe seizures were most frequently captured when seizures were induced by music on electroencephalogram (3/4; 75%). Intravenous (IV) methylprednisolone and/or IV Ig (IVIG) was utilized in four patients, with one having greater than 50% reduction. Rituximab (n = 2) and mycophenolate (n = 1) were ineffective. Two patients underwent right temporal lobe resections but continued to have seizures. Vagus nerve stimulation was effective at reducing seizures in one patient by 50%, and an additional patient was seizure‐free by avoiding provoking music. Right temporal lobe epilepsy was more common among patients with musicogenic epilepsy when compared to nonmusicogenic GAD65 epilepsies (n = 71, 89% vs. 47%, p = .03). GAD65‐IgG should be tested in patients with musicogenic epilepsy, given implications for management and screening for comorbid autoimmune conditions.
Paraneoplastic neurological syndrome: an evolving story

Neuro-Oncology Practice | February 24, 2021 | Volume: 8 | Issue: 4 | Pages: 362-374

10.1093/nop/npab002 | PMID 34277016

AbstractParaneoplastic neurological syndrome (PNS) comprises a group of neurological disorders that result from a misguided immune response to the nervous system triggered by a distant tumor. These disorders frequently manifest before the diagnosis of the underlying neoplasm. Since the first reported case in 1888 by Oppenheim, the knowledge in this area has evolved rapidly. Several classic PNS have been described, such as limbic encephalitis, paraneoplastic cerebellar degeneration, encephalomyelitis, opsoclonus-myoclonus, sensory neuronopathy, Lambert-Eaton Myasthenic syndrome, and chronic gastrointestinal dysmotility. It is now recognized that PNS can have varied nonclassical manifestations that extend beyond the traditional syndromic descriptions. Multiple onconeural antibodies with high specificity for certain tumor types and neurological phenotypes have been discovered over the past 3 decades. Increasing use of immune checkpoint inhibitors (ICIs) has led to increased recognition of neurologic ICI-related adverse events. Some of these resemble PNS. In this article, we review the clinical, oncologic, and immunopathogenic associations of PNS.